|
DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations.
The HRC, based at King's College London and the South London and Maudsley NHS Foundation Trust, is dedicated to advancing the diagnosis, care, and treatment of dementia through cutting-edge technologies. The Centre will leverage brain scanning, blood sampling, computerized testing, and digital tools to develop more effective and earlier methods of diagnosing dementia, aiming to reduce its societal impact.
Led by Professor Dag Aarsland, Director of the Centre for Healthy Brain Ageing at the Institute of Psychiatry, Psychology and Neuroscience, and Professor Clive Ballard of the University of Exeter, the HRC brings together academic excellence and industry innovation to tackle one of the most pressing challenges in neuroscience.
Commenting on the partnership, Dr. Charles Stacey, President & CEO of Cerecin, said:
"We are excited to join the HRC as an industry partner. King's College London has a world-class reputation in neuroscience research, and we believe that close collaboration between academia and industry is essential to accelerate innovation and bring impactful solutions to market. We are honored to join other industry leaders in advancing the future of brain health."
Dr. Richard Siow, Director of Ageing Research at King's (ARK) and Industry Lead for the NIHR HealthTech Research Centre in Brain Health, added: "We are pleased to welcome Cerecin as an industry partner. Cerecin is at the forefront of neurometabolism, a critical area of neuroscience research with the potential for significant impact to enhance healthy brain ageing. We look forward to working together to explore opportunities across Cerecin's pipeline and beyond."
As Cerecin advances the ALTER AD study, its pivotal Phase 3 program in Alzheimer's disease dementia with lead compound, tricaprilin, the company is actively pursuing strategic partnerships to strengthen its leadership in the field. These collaborations will support the development of both its current pipeline and future innovations, both independently and in concert with other industry leaders.
About Cerecin
Cerecin is a US-based clinical-stage biotechnology company focused on developing drugs that target the metabolic basis of neurological diseases. Cerecin's development programs leverage its extensive experience in neurology drug development and lipid science. Cerecin is supported by multinational partners; Nestlé, Wilmar and IOI. By combining the deep expertise of its leadership team with a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.
Cerecin's lead compound, tricaprilin, is currently in Phase 3, the ALTER AD study, for mild to moderate Alzheimer's disease dementia. Tricaprilin enhances ketone production by delivering medium-chain fatty acids directly to hepatic mitochondria, where they are rapidly metabolized to acetyl-CoA. This acetyl-CoA enters the ketogenesis pathway, producing ketone bodies such as β-hydroxybutyrate (BHB), which are transported to extrahepatic tissues, converted back to acetyl-CoA, and utilized in the TCA cycle to generate ATP. This mechanism bypasses impaired glucose metabolism and supports energy production in metabolically compromised cells.
For more information, visit www.cerecin.com or follow us on LinkedIn.
DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations.
The HRC, based at King's College London and the South London and Maudsley NHS Foundation Trust, is dedicated to advancing the diagnosis, care, and treatment of dementia through cutting-edge technologies. The Centre will leverage brain scanning, blood sampling, computerized testing, and digital tools to develop more effective and earlier methods of diagnosing dementia, aiming to reduce its societal impact.
Led by Professor Dag Aarsland, Director of the Centre for Healthy Brain Ageing at the Institute of Psychiatry, Psychology and Neuroscience, and Professor Clive Ballard of the University of Exeter, the HRC brings together academic excellence and industry innovation to tackle one of the most pressing challenges in neuroscience.
Commenting on the partnership, Dr. Charles Stacey, President & CEO of Cerecin, said:
"We are excited to join the HRC as an industry partner. King's College London has a world-class reputation in neuroscience research, and we believe that close collaboration between academia and industry is essential to accelerate innovation and bring impactful solutions to market. We are honored to join other industry leaders in advancing the future of brain health."
Dr. Richard Siow, Director of Ageing Research at King's (ARK) and Industry Lead for the NIHR HealthTech Research Centre in Brain Health, added: "We are pleased to welcome Cerecin as an industry partner. Cerecin is at the forefront of neurometabolism, a critical area of neuroscience research with the potential for significant impact to enhance healthy brain ageing. We look forward to working together to explore opportunities across Cerecin's pipeline and beyond."
As Cerecin advances the ALTER AD study, its pivotal Phase 3 program in Alzheimer's disease dementia with lead compound, tricaprilin, the company is actively pursuing strategic partnerships to strengthen its leadership in the field. These collaborations will support the development of both its current pipeline and future innovations, both independently and in concert with other industry leaders.
About Cerecin
Cerecin is a US-based clinical-stage biotechnology company focused on developing drugs that target the metabolic basis of neurological diseases. Cerecin's development programs leverage its extensive experience in neurology drug development and lipid science. Cerecin is supported by multinational partners; Nestlé, Wilmar and IOI. By combining the deep expertise of its leadership team with a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.
Cerecin's lead compound, tricaprilin, is currently in Phase 3, the ALTER AD study, for mild to moderate Alzheimer's disease dementia. Tricaprilin enhances ketone production by delivering medium-chain fatty acids directly to hepatic mitochondria, where they are rapidly metabolized to acetyl-CoA. This acetyl-CoA enters the ketogenesis pathway, producing ketone bodies such as β-hydroxybutyrate (BHB), which are transported to extrahepatic tissues, converted back to acetyl-CoA, and utilized in the TCA cycle to generate ATP. This mechanism bypasses impaired glucose metabolism and supports energy production in metabolically compromised cells.
For more information, visit www.cerecin.com or follow us on LinkedIn.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner
KUALA LUMPUR, Malaysia, April 21, 2026 /PRNewswire/ -- Hata, Malaysia's only dual-licensed digital asset exchange, today announced the closing of a USD 8 million (approximately RM31.6 million) Series A funding round led by Bybit, the world's second-largest cryptocurrency exchange by trading volume, alongside several prominent global family offices. The fundraise marks the beginning of a deep strategic collaboration between the two companies, one that goes beyond capital and signals a shared commitment to growing Malaysia's digital asset ecosystem responsibly and at scale.
"Malaysia is a strategically important market for Bybit, with one of the most digitally engaged populations in Southeast Asia and strong long term potential for digital asset adoption. We see Hata as the right partner to help serve Malaysian investors through a compliant and regulated platform. By combining Hata's local market leadership with Bybit's global strengths in technology and product innovation, we hope to accelerate the growth of Malaysia's digital asset and tokenised real world asset ecosystem." said Ben Zhou, Co-founder and CEO of Bybit.
The Series A round builds on Bybit's earlier participation in Hata's USD 4.2 million seed round, deepening a relationship that now extends into strategic collaboration. The round also saw participation from several global family offices with a strong focus on Southeast Asian technology and financial markets.
Hata will deploy the proceeds across three key areas on its platform, including strengthening its liquidity on its platform, accelerating user growth through its marketing and ecosystem initiatives and jointly developing innovative digital asset products tailored for Malaysians with Bybit.
"This partnership with Bybit marks a defining moment for Hata and for Malaysia's digital asset industry. Bybit's decision to lead this round and partner with us strategically is a strong validation of our belief that crypto should be built the right way, with proper licensing, rigorous compliance, and an unwavering commitment to investor protection. Together, we will combine Hata's regulated local platform with Bybit's global expertise in technology and product innovation to expand what is possible for Malaysian users." says David Low, CEO of Hata.
For more information about Hata and its latest developments, visit the official Hata page to be part of Malaysia's journey into the evolving world of digital assets.
About Hata
Hata is Malaysia's leading dual-licensed digital asset exchange, providing a secure, compliant and accessible platform for investors to buy, sell and custody digital assets. Founded by Malaysians, Hata operates under licenses from the Securities Commission Malaysia (SC) and the Labuan Financial Services Authority (LFSA), ensuring full regulatory compliance and robust security standards for users in Malaysia and globally.
Since its launch in May 2023 through the end of 2025, Hata has established itself as Malaysia's fastest-growing homegrown digital asset exchange, with more than 209,000 registered users. In 2025 alone, Hata processed RM1.04 billion in transaction volume, reflecting strong platform activity, while its assets under custody (AUC) have accumulated to RM86.3 million since launch to the end of 2025, peaking at RM115 million in September 2025 before broader market corrections.
Built on the principles of trust, transparency and technology, Hata is committed to setting new standards in Malaysia's digital asset ecosystem while expanding access to safe, compliant and affordable crypto trading across the region.
In 2025, Hata expanded its product suite with the launch of Staking, beginning with Solana (SOL), enabling users to earn rewards while contributing to blockchain network security. Together with its Auto-Invest (DCA) feature, Hata continues to introduce innovative tools that empower Malaysians and institutions to build sustainable, long-term digital wealth.
Visit hata.io to learn more.
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit offers a comprehensive suite of products including spot and derivatives trading, staking, copy trading, and institutional services. Renowned for its regulated custody, deep liquidity, and innovative product development, Bybit is committed to bridging the gap between traditional finance and decentralised finance across global markets.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Hata Completes US$8 Million Series A Financing Led by Bybit
